Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 9/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30563659 | 1.00 | ACHE (0.60) | ACHEDRD2DRD3CYP19A1CYP11B1 | |
| SCHEMBL269087 | 1.00 | ACHE (0.60) | ACHEDRD2DRD3CYP19A1CYP11B1 | |
| SCHEMBL30563644 | 1.00 | ACHE (0.60) | ACHEDRD2DRD3CYP19A1CYP11B1 | |
| SCHEMBL2463469 | 1.00 | ACHE (0.60) | ACHEDRD2DRD3CYP19A1CYP11B1 | |
| Hydrochloric Acid SCHEMBL31186905 | 0.98 | ACHE (0.62) | ACHEDRD2DRD3CYP19A1CYP11B1 | |
| Hydrochloric Acid SCHEMBL30563660 | 0.98 | ACHE (0.62) | ACHEDRD2DRD3CYP19A1CYP11B1 | |
| Hydrochloric Acid SCHEMBL5969966 | 0.98 | ACHE (0.62) | ACHEDRD2DRD3CYP19A1CYP11B1 | |
| Hydrochloric Acid SCHEMBL5970546 | 0.98 | ACHE (0.62) | ACHEDRD2DRD3CYP19A1CYP11B1 | |
| SCHEMBL30402024 | 0.90 | ACHE (0.62) | ACHEDRD2DRD3HTR2AHTR2C | |
| SCHEMBL606901 | 0.90 | ACHE (0.62) | ACHEDRD2DRD3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150339-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2024-05-09 | — | — | US | disclosed |
| EP-4291557-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2023-12-20 | — | — | EP | disclosed |
| CN-116848107-A | Compounds and their use as PDE4 activators | 米罗尼德有限公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2022172037-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2022-08-18 | — | — | WO | disclosed |
| CN-105087743-A | Preparation method of R-6-methoxy-1-aminoindan | CHEN YONGJUN | 2015-11-25 | — | — | CN | disclosed |
| CN-105085285-A | Method for preparing R-6-methoxy-1-aminoindane | WU LING | 2015-11-25 | — | — | CN | disclosed |
| CN-105087743-A | Preparation method of R-6-methoxy-1-aminoindan | CHEN YONGJUN | 2015-11-25 | — | — | CN | disclosed |
| CN-105085285-A | Method for preparing R-6-methoxy-1-aminoindane | WU LING | 2015-11-25 | — | — | CN | disclosed |
| CN-105063162-A | Preparation of R-6-methoxy-1-aminoindane through resolution | CHEN YONGJUN | 2015-11-18 | — | — | CN | disclosed |
| CN-105063162-A | Preparation of R-6-methoxy-1-aminoindane through resolution | CHEN YONGJUN | 2015-11-18 | — | — | CN | disclosed |
| US-5994408-A | THERAPY FOR PARKINSON'S DISEASE; ANTICONVULSANT | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-11-30 | — | — | US | disclosed |
| EP-0738149-A4 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMA (IL) | 1999-10-27 | — | — | EP | disclosed |
| US-5914349-A | ANTICONVULSANTS, EPILEPSY AND COGNITIVE AGENTS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-06-22 | — | — | US | disclosed |
| US-5880159-A | TREATING ACUTE NEUROLOGICAL TRAUMATIC DISORDER OR NEUROTRAUMA | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-03-09 | — | — | US | disclosed |
| US-5877218-A | PARKINSON'S DISEASE; ANTIEPILEPSY AGENTS; ANTICONVULSANTS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-03-02 | — | — | US | disclosed |
| US-5877221-A | TREATING DEMENTIA | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-03-02 | — | — | US | disclosed |
| US-5639913-A | TREATMENT OF PARKINSON'S DISEASE, DEMENTIA, EPILEPSY | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1997-06-17 | — | — | US | disclosed |
| EP-0738149-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-10-23 | — | — | EP | disclosed |
| WO-1996021640-A1 | OPTICALLY ACTIVE AMINOINDANE DERIVATIVES AND PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-07-18 | — | — | WO | disclosed |
| WO-1995018617-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150339-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE4B, PDE4C | ACHE 219/4885DRD2 2287/4885DRD3 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.